Pedro R. Florindo

Pedro R. Florindo

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2015 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
PFPedro R. Florindo
Pedro R. Florindo
DPDiane M. Pereira
Diane M. Pereira
PBPedro M. Borralho
Pedro M. Borralho
Cecilia MP RodrigugesCecilia MP Rodriguges
Cecilia MP Rodriguges
MPManuel E. Minas da Piedade
Manuel E. Minas da Piedade
Ana FernandesAna Fernandes
Ana Fernandes

1 March 2009 in Journal of Inorganic Biochemistry
Verified
Journal Article
Closed access
MGM. Helena Garcia
M. Helena Garcia
Tânia S. MoraisTânia S. Morais
Tânia S. Morais
PFPedro R. Florindo
Pedro R. Florindo
MPManuel E. Minas da Piedade
Manuel E. Minas da Piedade
VMVirtudes Moreno
Virtudes Moreno
VNVeronique Noe
Veronique Noe

25 April 2022 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
Ana ChegãoAna Chegão
Ana Chegão
MGMariana Guarda
Mariana Guarda
BABruno M. Alexandre
Bruno M. Alexandre
LSLiana Shvachiy
Liana Shvachiy
MTMariana Temido-Ferreira
Mariana Temido-Ferreira
Hugo Vicente MirandaHugo Vicente Miranda
Hugo Vicente Miranda
Alpha-synuclein (aSyn) is a central player in the pathogenesis of synucleinopathies due to its accumulation in typical protein aggregates in the brain. However, it is still unclear how it contributes to neurodegeneration. Type-2 diabetes mellitus is a risk factor for Parkinson’s disease (PD). Interestingly, a common molecular alteration among these disorders is the age-associated increase in protein glycation. We hypothesized that glycation-induced neuronal dysfunction is a contributing factor in synucleinopathies. Here, we dissected the impact of methylglyoxal (MGO, a glycating agent) in mice overexpressing aSyn in the brain. We found that MGO-glycation potentiates motor, cognitive, olfactory, and colonic dysfunction in aSyn transgenic (Thy1-aSyn) mice that received a single dose of MGO via intracerebroventricular injection. aSyn accumulates in the midbrain, striatum, and prefrontal cortex, and protein glycation is increased in the cerebellum and midbrain. SWATH mass spectrometry analysis, used to quantify changes in the brain proteome, revealed that MGO mainly increase glutamatergic-associated proteins in the midbrain (NMDA, AMPA, glutaminase, VGLUT and EAAT1), but not in the prefrontal cortex, where it mainly affects the electron transport chain. The glycated proteins in the midbrain of MGO-injected Thy1-aSyn mice strongly correlate with PD and dopaminergic pathways. Overall, we demonstrated that MGO-induced glycation accelerates PD-like sensorimotor and cognitive alterations and suggest that the increase of glutamatergic signaling may underly these events. Our study sheds new light into the enhanced vulnerability of the midbrain in PD-related synaptic dysfunction and suggests that glycation suppressors and anti-glutamatergic drugs may hold promise as disease-modifying therapies for synucleinopathies.

19 December 2012 in Chemical Communications
Verified
Journal Article
Open access
PDF file
MAMercedes Amat
Mercedes Amat
CRCarlos Ramos
Carlos Ramos
Maria PerezMaria Perez
Maria Perez
EMElies Molins
Elies Molins
PFPedro R. Florindo
Pedro R. Florindo
JBJoan Bosch
Joan Bosch
Starting from (S)-tryptophanol, a formal synthesis of ent-rhynchophylline and ent-isorhynchophylline, involving stereoselective cyclocondensation, spirocyclization, and alkylation reactions, and the final adjustment of the oxidation level at the oxindole and piperidine moieties, is reported.

1 January 2010 in Bioinorganic Chemistry and Applications
Verified
Journal Article
Open access
PDF file
VMVirtudes Moreno
Virtudes Moreno
JLJulia Lorenzo
Julia Lorenzo
Francesc Xavier AvilesFrancesc Xavier Aviles
Francesc Xavier Aviles
MGM. Helena Garcia
M. Helena Garcia
JRJoão P Ribeiro
João P Ribeiro
MRMaria Paula Robalo
Maria Paula Robalo
Four cationic ruthenium(II) complexes with the formula , with L = 5‐phenyl‐1H‐tetrazole (TzH) 1, imidazole (ImH) 2, benzo[1,2‐b;4,3‐b′] dithio‐phen‐2‐carbonitrile (Bzt) 3, and [5‐(2‐thiophen‐2‐yl)‐vinyl]‐thiophene‐2‐carbonitrile] (Tvt) 4 were prepared and characterized in view to evaluate their potentialities as antitumor agents. Studies by Circular Dichroism indicated changes in the secondary structure of ct‐DNA. Changes in the tertiary structure of pBR322 plasmid DNA were also observed in gel electrophoresis experiment and the images obtained by atomic force microscopy (AFM) suggest strong interaction with pBR322 plasmid DNA; the observed decreasing of the viscosity with time indicates that the complexes do not intercalate between DNA base pairs. Compounds 1, 2, and 3 showed much higher cytotoxicity than the cisplatin against human leukaemia cancer cells (HL‐60 cells).